Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e471.
   PubMed Web of Science ®Google Scholar
• Nilsson E, Anderson H, Sargenti K, et al. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol. 2019;54(8):1027–1032.
   PubMed Web of Science ®Google Scholar
• Goh MJ, Kang W, Kim KM, et al. Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scand J Gastroenterol. 2022;57(1):70–77.
   PubMed Web of Science ®Google Scholar
• Negro F. Natural history of NASH and HCC. Liver Int. 2020;40(Suppl 1):72–76.
   PubMed Web of Science ®Google Scholar
• Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35(5):862–869.
   PubMed Web of Science ®Google Scholar
• Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28(1):110–122.
   PubMed Web of Science ®Google Scholar
• Hagström H, Lindfors A, Holmer M, et al. Etiologies and outcomes of cirrhosis in a large contemporary cohort. Scand J Gastroenterol. 2021;56(6):727–732.
   PubMed Web of Science ®Google Scholar
• Huo TI, Lee PC, Huang YH, et al. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol. 2006;40:543–550.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
   PubMed Web of Science ®Google Scholar
• Ho SY, Hsu CY, Liu PH, et al. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver Int. 2020;40(1):205–214.
   PubMed Web of Science ®Google Scholar
• Huo TI. ALBI grade as a new player in hepatocellular carcinoma. J Chin Med Assoc. 2019;82(1):1.
   PubMed Web of Science ®Google Scholar
• Ho SY, Hsu CY, Liu PH, et al. Albumin-bilirubin (ALBI) grade-based nomogram for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci. 2021;66(5):1730–1738.
   PubMed Web of Science ®Google Scholar
• Fujita K, Oura K, Yoneyama H, et al. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatol Res. 2019;49(7):731–742.
   PubMed Web of Science ®Google Scholar
• Kariyama K, Nouso K, Hiraoka A, et al. EZ-ALBI score for predicting hepatocellular carcinoma prognosis. Liver Cancer. 2020;9(6):734–743.
   PubMed Web of Science ®Google Scholar
• Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13(3):594–601.e591.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–838.
   PubMed Web of Science ®Google Scholar
• Zou H, Wen Y, Yuan K, et al. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int. 2018;38(3):494–502.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Walker AJ, et al. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis c virus infection. J Viral Hepat. 2021;28(1):168–176.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei integrated scoring system. J Hepatol. 2010;53(1):108–117.
   PubMed Web of Science ®Google Scholar
• Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis. 2018;38(3):242–251.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Liu PH, Ho SY, et al. Metastasis in patients with hepatocellular carcinoma: prevalence, determinants, prognostic impact and ability to improve the Barcelona clinic liver cancer system. Liver Int. 2018;38(10):1803–1811.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Tsuji K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer. 2019;8(2):121–129.
   PubMed Web of Science ®Google Scholar
• Ho SY, Liu PH, Hsu CY, et al. Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res. 2021;51(11):1129–1138.
   PubMed Web of Science ®Google Scholar
• Kokudo T, Hasegawa K. Evaluating the liver function of patients with hepatocellular carcinoma. Hepatol Res. 2021;51(11):1095–1096.
   PubMed Web of Science ®Google Scholar
• Pourhoseingholi MA, Hajizadeh E, Moghimi Dehkordi B, et al. Comparing cox regression and parametric models for survival of patients with gastric carcinoma. Asian Pac J Cancer Prev. 2007;8(3):412–416.
   PubMedGoogle Scholar
• Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9(5):428–433. quiz e450.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Lee YH, Liu PH, et al. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLOS One. 2014;9(2):e89373.
   PubMed Web of Science ®Google Scholar
• Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56(6):1384–1391.
   PubMed Web of Science ®Google Scholar
• Jun TW, Yeh ML, Yang JD, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018;38(5):895–902.
   PubMed Web of Science ®Google Scholar
• Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46(10):1230–1237.
   PubMed Web of Science ®Google Scholar